Yakult Honsha Co., LTD   Report issue

For profit Phase 2 Phase 3 Phase 4
Founded: Tokyo Japan (1935)
Status: No NME R&D (1935)

Organization Overview

First Clinical Trial
2000
NCT00142350
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Yakult Europe BV | Yakult Honsha Co., LTD | Yakult Honsha European Research Center, ESV | Yakult U.S.A. Inc.

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 2)

Carcinoma, Hepatocellular (Phase 2)

Colorectal Neoplasms (Phase 2)

Constipation (Phase 4)

Diarrhea (Phase 4)

Influenza, Human (Phase 4)

Respiratory Tract Infections (Phase 4)

Rhinitis (Phase 2)

Rhinitis, Allergic (Phase 2)

Rhinitis, Allergic, Seasonal (Phase 2)

Stomach Neoplasms (Phase 3)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 20
  • # of Trial APIs: 18